Bristol's Pravachol (pravastatin) reduces MI risk by 31%, West of Scotland study reports.

Executive Summary

BRISTOL-MYERS SQUIBB's PRAVACHOL REDUCES NONFATAL MI AND CHD DEATH BY 31%, from 7.9% to 5.5%, compared to placebo in men with hypercholesterolemia and no history of myocardial infarction, according to results of the West of Scotland Coronary Prevention Study reported Nov. 15 at the American Heart Association annual meeting in Anaheim and published in the Nov. 16 issue of The New England Journal of Medicine. The study, presented by James Shepherd, MD, University of Glasgow, also found that Pravachol (pravastatin) reduced the risk for heart attack alone compared to placebo by 31%, from 6.5% to 4.6%.